HC Wainwright restated their hold rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report issued on Thursday, AnalystRatings.com reports. The brokerage currently has a $147.00 price target on the specialty pharmaceutical company’s stock.
“Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10% WACC discount rate, and negative 3.5% terminal growth after 2022 given conservatively assumed modest Xyrem franchise headwinds partially offset by other products’ continued growth.”,” the firm’s analyst commented.
Other research analysts also recently issued reports about the company. BMO Capital Markets set a $208.00 price objective on Jazz Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, July 3rd. Wells Fargo & Co reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Monday, June 17th. Barclays increased their target price on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an overweight rating in a report on Wednesday. Zacks Investment Research lowered Jazz Pharmaceuticals from a buy rating to a hold rating in a report on Monday, May 6th. Finally, ValuEngine raised Jazz Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of Buy and a consensus target price of $178.44.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a return on equity of 28.07% and a net margin of 32.99%. The firm had revenue of $534.13 million during the quarter, compared to analysts’ expectations of $507.23 million. During the same quarter last year, the business posted $3.49 earnings per share. The firm’s revenue was up 6.7% on a year-over-year basis. Research analysts forecast that Jazz Pharmaceuticals will post 13.24 EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Prime Capital Investment Advisors LLC purchased a new position in shares of Jazz Pharmaceuticals during the first quarter worth about $27,000. Carroll Financial Associates Inc. grew its holdings in shares of Jazz Pharmaceuticals by 166.7% during the first quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 125 shares during the last quarter. Machina Capital S.A.S. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $29,000. Finally, Signaturefd LLC grew its holdings in shares of Jazz Pharmaceuticals by 56.3% during the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 72 shares during the last quarter. 89.99% of the stock is currently owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.